TY - JOUR
T1 - How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC
AU - Savarese, Gianluigi
AU - Lindberg, Felix
AU - Cannata, Antonio
AU - Chioncel, Ovidiu
AU - Stolfo, Davide
AU - Musella, Francesca
AU - Tomasoni, Daniela
AU - Abdelhamid, Magdy
AU - Banerjee, Debasish
AU - Bayes‐Genis, Antoni
AU - Berthelot, Emmanuelle
AU - Braunschweig, Frieder
AU - Coats, Andrew J.S.
AU - Girerd, Nicolas
AU - Jankowska, Ewa A.
AU - Hill, Loreena
AU - Lainscak, Mitja
AU - Lopatin, Yury
AU - Lund, Lars H.
AU - Maggioni, Aldo P.
AU - Moura, Brenda
AU - Rakisheva, Amina
AU - Ray, Robin
AU - Seferovic, Petar M.
AU - Skouri, Hadi
AU - Vitale, Cristiana
AU - Volterrani, Maurizio
AU - Metra, Marco
AU - Rosano, Giuseppe M.C.
PY - 2024/5/22
Y1 - 2024/5/22
N2 - Guideline‐directed medical therapy (GDMT) in patients with heart failure and reduced ejection fraction (HFrEF) reduces morbidity and mortality, but its implementation is often poor in daily clinical practice. Barriers to implementation include clinical and organizational factors that might contribute to clinical inertia, i.e. avoidance/delay of recommended treatment initiation/optimization. The spectrum of strategies that might be applied to foster GDMT implementation is wide, and involves the organizational set‐up of heart failure care pathways, tailored drug initiation/optimization strategies increasing the chance of successful implementation, digital tools/telehealth interventions, educational activities and strategies targeting patient/physician awareness, and use of quality registries. This scientific statement by the Heart Failure Association of the ESC provides an overview of the current state of GDMT implementation in HFrEF, clinical and organizational barriers to implementation, and aims at suggesting a comprehensive framework on how to overcome clinical inertia and ultimately improve implementation of GDMT in HFrEF based on up‐to‐date evidence.
AB - Guideline‐directed medical therapy (GDMT) in patients with heart failure and reduced ejection fraction (HFrEF) reduces morbidity and mortality, but its implementation is often poor in daily clinical practice. Barriers to implementation include clinical and organizational factors that might contribute to clinical inertia, i.e. avoidance/delay of recommended treatment initiation/optimization. The spectrum of strategies that might be applied to foster GDMT implementation is wide, and involves the organizational set‐up of heart failure care pathways, tailored drug initiation/optimization strategies increasing the chance of successful implementation, digital tools/telehealth interventions, educational activities and strategies targeting patient/physician awareness, and use of quality registries. This scientific statement by the Heart Failure Association of the ESC provides an overview of the current state of GDMT implementation in HFrEF, clinical and organizational barriers to implementation, and aims at suggesting a comprehensive framework on how to overcome clinical inertia and ultimately improve implementation of GDMT in HFrEF based on up‐to‐date evidence.
KW - Guidelines‐directed medical therapy
KW - Heart failure
KW - Heart failure with reduced ejection fraction
KW - Clinical inertia
KW - Implementation
U2 - 10.1002/ejhf.3295
DO - 10.1002/ejhf.3295
M3 - Article
SN - 1388-9842
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
ER -